← All trials
NCT04134403
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2019
- Primary completion
- Nov 1, 2020
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Baqiyatallah Medical Sciences UniversityLead sponsor
- University of TehranCollaborator
- Baqiyatallah Medical Sciences UniversityReponsible party - principal investigator
- East Carolina UniversityOverall official - principal investigator
- Hamadan University of Medical ScienceCollaborator
- Baqiyatallah Medical Sciences UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.